the effectiveness of topiramate in the treatment of amphetamine and methamphetamine use disorder: a randomized controlled trial

Objective: limited studies have yet evaluated the effectiveness of topiramate in the treatment of amphetamine and methamphetamine addiction. therefore, the aim of this study was to investigate the effectiveness of topiramate in the treatment of patients with this disorder. methods: in this randomized, double-blind, placebo-controlled clinical trial, 52 patients with amphetamine and methamphetamine use disorder, within the age range of 16-60 years, were randomly divided into an intervention group (n = 26) and a placebo group (n = 26). the intervention group was treated with topiramate tablets with a starting dose of 50 mg, which was gradually increased to the target dose of 200 mg. the control group was treated with placebo. the duration of drug intervention in this clinical trial was 12 weeks, and all participants were evaluated before the intervention and 2, 4, 6, 8, 10, and 12 weeks after beginning the intervention. the beck depression inventory, drug use temptation questionnaire, urine test, and side effects questionnaire were used as outcome measures to assess the patients. the data were analyzed using chi-square, independent t-test, and analysis of variance with repeated measurements. results: there was no significant difference between the intervention and placebo groups in depression at the beginning of the treatment and at the 4th, 8th, and 12th weeks after the intervention (p > 0.05). the urine test also showed no significant difference between the two groups at any of the evaluation stages (p > 0.05). although there was no significant difference between the two groups in the drug use temptation results at the beginning and the 2nd, 4th and 6th weeks (p > 0.05), the level of drug temptation in the intervention group was significantly lower than the placebo group in the 8th, 10th, and 12th weeks (p < 0.05). conclusion: topiramate can be effective in reducing the desire to use amphetamine and methamphetamine. however, further studies are needed to confirm these results.